Objective To investigate the effects of pioglitazone and metformin treatment during pre-diabetic period for the prevention of diabetes in a rat model.
Introduction
Type 2 diabetes mellitus is a chronic, slowly progressive disease that is caused by both insulin deficiency and insulin resistance. The incidence of diabetes has been increasing rapidly, and the cost of managing the chronic complications associated with diabetes is also becoming an enormous problem. Therefore, it would be important to identify the high-risk patients in pre-diabetic stage and focus on the prevention of type 2 diabetes through life-style modifications or medication [1] .
The male Otsuka Long-Evans Tokushima Fatty (OLETF) rat is a good animal model for examining obese type 2 diabetes mellitus. These rats are characterized by their polygenic traits, chronic, and late onset of disease [2, 3] . Between 20 and 28 weeks of age, they begin to have overt diabetes, and around the age of 40 weeks, pancreatic beta cell function apparently decreases and becomes hypoinsulinaemic with defects in insulin secretion [3] .
Several clinical and animal studies have shown that troglitazone, peroxisome proliferator-activated receptor (PPAR)-γ agonist, prevents the progression of type 2 diabetes through various mechanisms [4] [5] [6] [7] [8] . Pioglitazone belongs to the thiazolidinedione class of drugs and binds to a nuclear receptor called the PPAR-γ . It enhances the expression of multiple genes encoding the proteins that modulate glucose and lipid metabolism [9, 10] . Pioglitazone increases insulin sensitivity mainly at the level of muscle and adipose tissue, with some effects on the liver. However, the accurate mechanism of this drug is still unclear [11] [12] [13] . Pioglitazone is also known to have some effects related to the PPAR-α receptor. This cross reactivity to the PPAR-α may explain why pioglitazone more effectively lowers triglyceride levels in this class [14, 15] . Metformin is also widely used as an insulin sensitizer in clinics; There are several studies which have shown that metformin can prevent diabetes mellitus and hypertension in animals and humans [16] [17] [18] .
Therefore, the aims of our study were to investigate and compare the metabolic effects of well-known insulin sensitizers, pioglitazone and metformin, and their effectiveness in preventing the development of diabetes in genetically determined diabetic OLETF rats with chronic treatment from the pre-diabetic periods.
Materials and methods

Animals and diet
Male OLETF rats and their control counterpart, male LongEvans Tokushima Otsuka (LETO) rats, aged 4 weeks, were kindly provided from Otsuka Pharmaceuticals, Japan. They were maintained in a temperature-controlled environment with a 12-h light/dark cycle and supplied with standard rat chow diet consisting of 61% carbohydrate, 26% protein and 13% fat and tap water ad libitum. They were maintained according to the ethical guidelines of this institution. The Committee on Animal Investigation of the Yonsei University approved this experimental protocol.
Administration of pioglitazone and metformin
, which is known as a PPAR-γ agonist, was kindly provided by Dr Hiroshi Fukui (Takeda Chemical Industry Co., Osaka, Japan). Standard rat chow was pulverized to a fine powder and divided into two groups, pioglitazone and metformin. The respective drugs were added and thoroughly mixed to a final concentration of 0.015% (wt/wt) [piolitazone 150.02 mg/pulverized chow 1 kg] and 0.677% (wt/wt) [metformin 6.816 g/pulverized chow 1 kg], respectively. These concentrations were chosen based on a preliminary study that adjusted the pioglitazone and metformin doses to 10 and 300 mg/kg/day, respectively. The chow for control rats was prepared in a similar manner without the addition of drugs.
Experimental protocol
At the age of 18 weeks, the OLETF rats were randomly divided. The LETO control rats (LETO) and OLETF control rats (O-C) received standard chow diet only from birth to 28 weeks (n = 10 at each). The Pioglitazone treated OLETF rats (O-P) were maintained on the pioglitazonecontaining chow diet (n = 20, 0.015%, wt/wt) and the metfomin treated OLETF rats (O-M) received metformincontaining chow (n = 20, 0.677%, wt/wt) from 18 to 28 weeks of age. All the rats were housed two to a cage and were given free access to chow and water. The body weight and food intake of the OLETF and LETO rats were monitored periodically from the age of 18 to 28 weeks. The mean food intake was estimated to be the amount of food consumed per cage. At the ages of 18 and 28 weeks, an oral glucose tolerance test (OGTT) was performed in all groups, respectively. A euglycaemic hyperinsulinaemic clamp test was performed at the age of 28 weeks. After the euglycaemic clamp test, all rats were sacrificed and the abdomen was quickly opened to remove the whole pancreas (n = 10 from each group). The abdominal subcutaneous fat pad and epididymal visceral fat pad were dissected and weighed.
Plasma glucose and lipid measurements
Blood was withdrawn from the tail vein and the blood sample was placed on ice prior to centrifugation for 10 min. The supernatant was retained and stored at −80 • C until the glucose, insulin, total cholesterol (TC), triglyceride (TG), and non-esterified free fatty acids (FFAs) levels were measured. The plasma glucose level was measured by a glucose-oxidase method. The plasma insulin concentration was measured by a radioimmunoassay using the double-antibody method with a commercially available radioimmunoassay kit (Linco Research). The plasma concentrations of total cholestrol, TG, and FFAs were measured by an enzymatic colorimetric method using commercially available kits. body temperature was maintained at 37-38 • C with a heating lamp. The right femoral artery was catheterized for blood sampling. A blood sample was obtained 20 min after surgery to determine the basal blood glucose concentration. Insulin was infused at a constant rate of 6 mU/kg/m via the left femoral artery with an infusion pump (Harvard Apparatus 22; Harvard, Natick, MA). Human insulin was dissolved in 0.9% NaCl containing 1% BSA. The glucose (25%, wt/vol) infusion was begun 5 min after the insulin infusion through a second IV catheter with its infusion rate adjusted to sustain the plasma glucose level at −6 mmol/l using the PACBERG algorithm. Subsequently, 25 µl blood was sampled from the right femoral artery at 10-min intervals, and the blood glucose concentrations were determined within 30 s using a glucose analyser [19, 20] .
Pancreas Insulin content
After a 2-h euglycaemic clamp test, the rats were sacrificed (n = 7 in each LETO and O-C group, n = 10 in each O-P and O-M group) and the whole pancreas was rapidly dissected free from the surrounding tissues, weighed in air, frozen in liquid N2, and stored at −70 • C. The frozen whole pancreata were homogenized at 20 500 rpm for 20 s using a tissue homogenizer (Ultra-Turrax T24, IKALabartechnik, Staufen, Germany) in a 10 times volume (10 ml buffer solution per 1 g tissue) of an acid ethanol buffer (1.5 Ml HCL 12 mol/l in 100 ml 70% [vol/vol] ethanol) and incubated overnight at 4 • C for a further extraction. On the next day, the samples were centrifuged at 3000 g for 15 min at 4 • C, and the supernatants were diluted 1 : 100 and refrozen at −70 • C until needed for the assay. The insulin level was measured with an insulin RIA kit for rat insulin and was normalized with the pancreas and the total body weight (g%).
Histopathological examination
Pancreatic tissues (n = 3 in each LETO and O-C group, n = 10 in each O-P and O-M group) were fixed overnight in 10% formaldehyde solution and embedded in paraffin for histological examination. Paraffin sections were stained with hematoxylin-eosin (H&E) stain and Masson's trichrome stain to evaluate the degree of fibrotic change. All histological samples were examined by the same pathologist who was blinded to the treatment.
Statistical analysis
The inter-group comparisons were performed using an independent samples t-test and a one-way ANOVA. Paired samples were compared with using a paired ttest. Significance was defined as a p value <0.05. The group data is expressed as a mean ± SEM. The statistical analyses were performed using the SPSS 10.0 software package (SPSS, Inc., Chicago, IL).
Results
Food consumption and body weight changes
During the period of study, the mean daily food intake of the LETO and OLETF rats was similar (28.3 ± 1.1 (vs) 29.5 ± 1.5 g/d, P = NS). Chronic treatment with pioglitazone and metformin did not influence the quantity of food intake (26.9 ± 1.3, 26.8 ± 1.6 g/d, respectively, Table 1 ). The O-P gained more weight at the end of the study than the O-C (600 ± 14 (vs) 528 ± 14 g in O-C rats, p < 0.05). Meanwhile, the O-M failed to gain weight compared to the control-OLETF rats (506 ± 18 g (vs) 528 ± 14 g in O-C rats, p < 0.05, Table 1 ).
Body fat distribution
The prominent weight gain in the OLETF rats after pioglitazone treatment was primarily due to the increase in the subcutaneous fat deposit rather than the visceral one (4.7 ± 0.1 (vs) 3.0 ± 0.3 g% in O-C rats, p < 0.05, Table 1 ). The epididymal fat contents were markedly lower in the metformin-treated OLETF rats compared to the other group (1.8 ± 0.1 (vs) 2.5 ± 0.1 g% in O-P rats, p < 0.05, Table 1 ).
Serum insulin and glucose response to oral glucose load
At the beginning of the study, the baseline plasma glucose concentration and glucose intolerance of the LETO and OLETF rats were similar (Table 1, Figure 1(A) ). At the end of the study, the fasting plasma glucose levels of the O-C rats were slightly higher than that in the LETO rats (5.81 ± 0.11 (vs) 4.43 ± 0.21 mmol/l, p < 0.05, Table 1 ). However, after an oral glucose load, the blood glucose level was remarkably higher in the O-C rats than the LETO rats (Figure 1(B) ). In contrast to the O-C rats, the O-P rats showed almost normal fasting and glucose-loaded blood glucose levels compared to those of the LETO rats (Figure 1(B) ). In the case of the O-M rats, the fasting glucose level was similar to those in the O-P rats, in which the post glucose-loaded levels were between those of the O-C and O-P rats, but the peak blood glucose levels was almost 16 mmol/l at 30 min after the glucose load (Figure 1(B) ).
From an analysis of the glucose area under the curve (AUC), the O-P rats showed a marked improvement in the glucose utilization rather than the O-M rats (7.15 ± 0.98 (vs) 11.02 ± 0.75 mmol/l/h, respectively, p < 0.05, Table 1 ).
Changes of plasma lipid concentrations
At the pre-diabetic stage of the 18-week-old OLETF rats, the fasting total cholesterol and triglyceride plasma concentrations of the OLETF and LETO rats were similar (Table 1) . However, the fasting plasma-free fatty acid levels of the OLETF rats were markedly higher than the LETO rats. At the end of the study, the fasting total cholesterol, triglyceride, and free fatty acid plasma levels in the O-C rats were remarkably elevated compared to those of the LETO rats (Table 1) . After 10 weeks of pioglitazone administration, the lipid profiles of the O-P rats, particularly the serum triglyceride levels and FFAs, were dramatically improved and reversed up to the lower levels than those of the LETO control rats (TG 0.46 ± 0.04 (vs) 0.88 ± 0.05 mmol/l in LETO, P < 0.05, Table 1 ). In the O-M rats, the plasma lipid concentrations were also reduced, but not as profound as those in O-P rats (Table 1) .
Glucose disposal rate during euglycaemic clamp test
In the O-C rats, the glucose disposal rate was significantly lower during the euglycaemic clamp test than in the non-diabetic LETO rats (20.6 ± 0.5 (vs) 26.3 ± 0.4 mg/min/kg, p < 0.05, Figure 2 ). Both the O-P and O-M rats recovered the glucose disposal rate up to the level of those in the LETO rats ( Figure 2 ).
Pancreas insulin contents
At the age of 28 weeks, the pancreatic insulin contents were significantly lower in the O-C rats than in the LETO rats. In the O-P rats, the amount of pancreatic insulin content was almost doubled compared to the O-C rats (22.9 ± 1.2 (vs) 11.4 ± 1.1 nmol/pancreas, p < 0.05, Figure 3 ), and was significantly increased compared to those in the LETO rats. In the O-M rats, the pancreatic insulin content was also higher than the O-C rats but was not as high as in the O-P rats (18.8 ± 1.3 (vs) 22.9 ± 1.2 nmol/pancreas in O-P rats, p < 0.05, Figure 3 ).
Histopathological changes
The pancreata of the O-C rats were hypertrophic, the islet cells were increased in number and structurally disarranged with early fibrosis at the age of 28 weeks (Figure 4(B) ). In the O-P rats, the structural changes in their pancreatic tissue were much less hypertrophic and fibrotic than that of the O-C rats (Figure 4(C) ). ß cell hypertrophy and fibrosis were also improved in the O-M rats, but compared with the O-P rats, more inflammatory cell infiltration and fibrosis were observed (Figure 4(D) ).
Discussion
This study demonstrated that a chronic treatment with pioglitazone in pre-diabetic OLETF rats prevents the 
(vs) control-OLETF rats (O-C). O-P, the pioglitazone treated OLETF rats; O-M, the metformin treated OLETF rats
development of diabetes, normalizes hyperlipidaemia and increases pancreatic insulin contents despite the prominent body weight gain. On the other hand, a long-term treatment with metformin during the pre-diabetic stage in OLETF rats does not completely reverse hyperglycaemia after glucose loading, but significantly improves glucose utilization with marked weight reduction. A previous study showed that the long-term administration of troglitazone in the OLETF rats prevents diabetes and insulin secretory defects. However, they did not report the marked weight changes in the troglitazone treated rats [7] . PPAR-γ agonist is known to promote preadipocyte growth and differentiation with subcutaneous adipocytes being more specific than visceral adipocytes, which results in a greater number of smaller, more insulin sensitive cells [21, 22] . In this study, after 10 weeks of pioglitazone administration, the OLETF rats show a marked weight gain, but the increased fat portions were mainly found in the subcutaneous fats rather than in the metabolically deleterious visceral fats (Table 1) . Miyazaki et al. reported that a shift in the fat distribution from the visceral or other area to subcutaneous adipose depots after a pioglitazone treatment is associated with an improvement in the hepatic and peripheral tissue sensitivity to insulin in type 2 diabetic patients [21] . This can explain the normal glucose tolerance in the pioglitazone-treated OLETF rats, despite their significant body weight gain in this study. In contrast, the metformin treated groups show a marked weight reduction compared to both the LETO and the other OLETF groups in this study. The marked reduced body weight arose mainly from the decreased visceral fat content (Table 1) . In other studies, metformin administration can lower blood pressure in the OLETF rats with an improvement in the insulin resistance and triglyceridaemia with a prominent weight reduction [17, 23] . Overall, metformin can ameliorate the insulin resistance in the OLETF rats possibly through the marked reduction in the visceral fats and enhancing the glucose utilization.
Hypertriglyceridaemia is known to reduce the amount of peripheral glucose utilization [24, 25] , inhibit glucose-stimulated insulin release [25, 26] and promote hepatic glucose production. Elevated triglyceride levels and ectopic fat accumulation are commonly observed in type 2 diabetes cases, and they have direct detrimental effect on the pancreatic beta cells, termed lipotoxicity [12, 26] . Therefore, an intensive correction of the dyslipidaemia can improve the insulin resistance and the beta cell function in type 2 diabetes [27] [28] [29] [30] [31] [32] [33] . OLETF rats develop visceral obesity and hypertriglyceridaemia at approximately 6 weeks, which is an age before glucose intolerance had been manifested [29] . In the course of diabetes in the OLETF rats, hypertriglyceridaemia might result in significant triglyceride storage in islets, which cause insulin secretion defects possibly by reducing the glucokinase activity [3] .
In this study, the dramatic effects of pioglitazone in lowering the FFAs, total cholesterol and triglyceride levels in the OLETF rats were observed. Pioglitazone reverses the serum triglyceride and FFAs levels to completely normal levels beyond the range in the non-diabetic LETO rats. Metformin also has a beneficial effect on the lipid profiles, but a marked reduction as observed in the pioglitazone treated groups, was not observed (Table 1) .
We performed a hyperinsulinaemic euglycaemic clamp test for measuring the level of glucose utilization in the skeletal muscle [19] . The glucose disposal rate was significantly improved after the pioglitazone and metformin treatment, respectively, compared to the O-C rats (Figure 2 ). When compared to previous studies, thiazolidinediones alone or combined with sulfonylurea improves both the glucose disposal rate in the skeletal muscle and beta cell function in the pancreas [28, 33] .
The pancreatic islet cells of the OLETF rats have periodic morphological changes according to their age, (1) a near normal stage with some sporadic changes in the same lobule, (2) large islet cells with hyperplasia of beta cells in the prediabetic period, (3) atrophy of the hyperplastic foci and a loss of beta cells in the later stage, (4) dense fibrosis and clustering of the islet cells [34] . The pancreas insulin content and histomorphological changes were measured at the age of 28 weeks in the OLETF rats. At that stage, hyperplastic pancreatic islet cells were observed in the OLETF rats, which were forced to secrete more insulin to overcome their loss of normal insulin sensitivity [34] [35] [36] .
It was interesting that we observed the conservation of pancreatic islet changes, from such change as islet hypertrophy and early fibrosis, in the O-P rats. We also observe the improvement of islets in the O-M rats, but more fibrotic changes than the pioglitazone treated group. This pathological improvement after 10 weeks of pioglitazone treatment might contribute that the pancreatic insulin content almost doubled compared to the O-C and non-diabetic LETO rats (Figure 3, Figure 4) . Considering that the pancreatic insulin content reflects the endogenous beta cell function precisely [33, 34] , the chronic treatment of pioglitazone during the pre-diabetic periods in the OLETF rats can preserve and compensate for the beta cell function with ameliorating the morphological deterioration of the pancreatic islets [36, 37] .
Our study has several limitations. First, we did not measure pancreatic TG contents in the pancreas of sacrificed animals, which could explain the direct effect of pioglitazone on the extra-fat deposition in pancreas and the beta cell function with normalizing serum lipid profile in OLETF rats. Second, we did not measure adipocytokines, such as leptin, adiponectin, IL-6 etc., which could influence the different mechanisms between pioglitazone and metformin treatment on the body weight changes and the fat redistribution of OLETF rats in this study.
The pre-diabetic long-term treatment with pioglitazone improves the postglycaemic insulin response at a normal level and completely prevents the development of diabetes in a type 2 diabetic OLETF rat model despite marked weight gain. The pancreatic insulin contents were doubled with preservation of islet cell pathology with the dramatic normalization of the dyslipidaemia and fat redistribution, which plays a different role in preventing diabetes in this model compared to the metformin treatment.
On the other hand, the chronic treatment of metformin in the prediabetic stage also improves fasting and postglycaemic glucose response, but not upto the level of the pioglitazone treated groups, which occurred mainly as a result of an improvement in visceral obesity with a marked weight reduction and by the enhancement of glucose utilization in the peripheral tissue.
